| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L Dahan, H Husum, O Mnie-Filali, J Arnt, P Hertel, N Haddjer. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. Journal of psychopharmacology (Oxford, England). vol 23. issue 2. 2009-07-28. PMID:18515444. |
effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. |
2009-07-28 |
2023-08-12 |
rat |
| L Dahan, H Husum, O Mnie-Filali, J Arnt, P Hertel, N Haddjer. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. Journal of psychopharmacology (Oxford, England). vol 23. issue 2. 2009-07-28. PMID:18515444. |
using in-vivo electrophysiological and behavioural paradigms in the rat, the effects of bifeprunox and aripiprazole were assessed on ventral tegmental area (vta) dopamine and dorsal raphe serotonin (5-ht) cell activity and on foot shock-induced ultrasonic vocalisation (usv). |
2009-07-28 |
2023-08-12 |
rat |
| L Dahan, H Husum, O Mnie-Filali, J Arnt, P Hertel, N Haddjer. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. Journal of psychopharmacology (Oxford, England). vol 23. issue 2. 2009-07-28. PMID:18515444. |
in vta, bifeprunox and aripiprazole decreased (by 20-50%) firing of dopamine neurons. |
2009-07-28 |
2023-08-12 |
rat |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. European journal of pharmacology. vol 607. issue 1-3. 2009-07-07. PMID:19217900. |
aripiprazole is the first dopamine d(2)/d(3) receptor partial agonist approved for use in the treatment of psychiatric disorders including schizophrenia, bipolar disorder, and unipolar depression in the us. |
2009-07-07 |
2023-08-12 |
human |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. European journal of pharmacology. vol 607. issue 1-3. 2009-07-07. PMID:19217900. |
in an effort to elucidate aripiprazole's pharmacological activity in relation to clinically relevant fluctuation of dopamine d(2) receptor reserves, we compared the properties of aripiprazole to other antipsychotics, quetiapine, clozapine, olanzapine, ziprasidone, risperidone and haloperidol, a dopamine d(2) receptor partial agonist, bifeprunox, dopamine d(3) receptor modulators, bp897 (n-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]naphthalene-2-carboxamide) and gr103691 (4'-acetyl-n-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]biphenyl-4-carboxamide), and a 5-ht(1a) partial agonist, buspirone using forskolin-stimulated camp accumulation in clonal chinese hamster ovary cell lines expressing low and high densities of human dopamine d(2s) receptors (hd(2s)-low and hd(2s)-high, respectively). |
2009-07-07 |
2023-08-12 |
human |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. European journal of pharmacology. vol 607. issue 1-3. 2009-07-07. PMID:19217900. |
in hd(2s)-high cells possessing receptor reserves, all antipsychotics except aripiprazole antagonized dopamine responses, and their antagonist potencies were less than those in hd(2s)-low cells treated with the equal dopamine concentration. |
2009-07-07 |
2023-08-12 |
human |
| Shih-Fen Chen, Yu-Chih Shen, Chia-Hsiang Che. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Progress in neuro-psychopharmacology & biological psychiatry. vol 33. issue 3. 2009-06-16. PMID:19302829. |
aripiprazole, a novel antipsychotic agent, has a unique pharmacological action (partial agonist) on the dopamine neurotransmission system. |
2009-06-16 |
2023-08-12 |
Not clear |
| Shih-Fen Chen, Yu-Chih Shen, Chia-Hsiang Che. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Progress in neuro-psychopharmacology & biological psychiatry. vol 33. issue 3. 2009-06-16. PMID:19302829. |
aripiprazole has high affinity for dopamine d2 and d3 receptors (drd2 and drd3). |
2009-06-16 |
2023-08-12 |
Not clear |
| J Adan-Manes, P Garcia-Paraju. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. Journal of clinical pharmacy and therapeutics. vol 34. issue 2. 2009-06-11. PMID:19250146. |
aripiprazole is a new generation antipsychotic drug with a partial agonist effect on dopamine d2 and d3 receptors. |
2009-06-11 |
2023-08-12 |
Not clear |
| J Adan-Manes, P Garcia-Paraju. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. Journal of clinical pharmacy and therapeutics. vol 34. issue 2. 2009-06-11. PMID:19250146. |
we conclude that clinicians should be cautious when adding aripiprazole to patients under treatment with dopamine antagonists with a high affinity for d2 and d3 receptors. |
2009-06-11 |
2023-08-12 |
Not clear |
| Livia Brusa, Antonio Orlacchio, Vincenzo Moschella, Cesare Iani, Giorgio Bernardi, Nicola Biagio Mercur. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Movement disorders : official journal of the Movement Disorder Society. vol 24. issue 1. 2009-06-04. PMID:19170197. |
aripiprazole (ap), a dopamine (da) d(2) receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (tbz), a da depletor, has been used to treat hyperkinesias in huntington's disease (hd). |
2009-06-04 |
2023-08-12 |
Not clear |
| J Costenti. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole]. L'Encephale. vol 35. issue 1. 2009-06-01. PMID:19250996. |
on the other hand, the occupation by aripiprazole of the d2 receptors that are not stimulated by dopamine (on account of an insufficient presynaptic dopaminergic activity) restores a certain amount of stimulation, which partly alleviates negative expressions of schizophrenia. |
2009-06-01 |
2023-08-12 |
Not clear |
| Philip Seema. Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole. Synapse (New York, N.Y.). vol 62. issue 12. 2009-05-26. PMID:18792990. |
dopamine d2(high) receptors moderately elevated by bifeprunox and aripiprazole. |
2009-05-26 |
2023-08-12 |
human |
| Philip Seema. Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole. Synapse (New York, N.Y.). vol 62. issue 12. 2009-05-26. PMID:18792990. |
because long-term antipsychotics elicit behavioral dopamine supersensitivity, the present study examined whether 7-9 days administration of partial dopamine d2 agonists with antipsychotic activity, bifeprunox and aripiprazole, could induce biochemical changes that suggest dopamine supersensitivity. |
2009-05-26 |
2023-08-12 |
human |
| Yu Liu, Hong-qiang Sun, Yan-ping Bao, Su-xia Li, Thomas J R Beveridge, Xiao-lan Di, Fu-de Yang, Lin L. Subjective, cognitive/psychomotor, and physiological effects of aripiprazole in Chinese light and heavy smokers. Drug and alcohol dependence. vol 101. issue 1-2. 2009-05-21. PMID:19070440. |
the partial dopamine d(2) receptor agonist aripiprazole has recently been tested as a treatment for stimulant and alcohol dependence in both animal and clinical studies. |
2009-05-21 |
2023-08-12 |
Not clear |
| Yu-Chih Shen, Shih-Fen Chen, Chia-Hsiang Chen, Chaucer C H Lin, Shaw-Ji Chen, Yu-Jung Chen, Sy-Ueng Lu. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. Journal of psychiatric research. vol 43. issue 6. 2009-05-13. PMID:18926547. |
aripiprazole, a novel antipsychotic agent, acts as a partial agonist at dopamine d2 receptors (drd2). |
2009-05-13 |
2023-08-12 |
Not clear |
| Su-xia Li, Yan Zou, Li-jing Liu, Ping Wu, Lin L. Aripiprazole blocks reinstatement but not expression of morphine conditioned place preference in rats. Pharmacology, biochemistry, and behavior. vol 92. issue 2. 2009-04-27. PMID:19353810. |
aripiprazole is an atypical antipsychotic drug primarily characterized by partial agonist activity at dopamine(da) d2 receptors and serotonin-1a (5-hydroxytryptamine, 5-ht1a) receptors and minimal side effects.based on its pharmacological profile, including stabilization of mesocorticolimbic da activity (a pathway implicated in drug addiction), we investigated the effects of aripiprazole on relapse to morphine seeking in rats. |
2009-04-27 |
2023-08-12 |
rat |
| Tsung-Tsair Yang, Su-Jane Wan. Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia. Synapse (New York, N.Y.). vol 62. issue 11. 2009-04-21. PMID:18720421. |
in addition, the dopamine d2 receptor antagonist haloperidol and the 5-ht 1a receptor antagonist way100635 all effectively blocked the aripiprazole or opc13857-mediated inhibition of 4-ap-evoked glutamate release. |
2009-04-21 |
2023-08-12 |
human |
| Tsung-Tsair Yang, Su-Jane Wan. Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia. Synapse (New York, N.Y.). vol 62. issue 11. 2009-04-21. PMID:18720421. |
together, these results suggest that aripiprazole and its human metabolite opc14857 inhibit glutamate release from rat prefrontocortical nerve terminals, likely by the activation of dopamine d2 and 5-ht 1a receptors, which subsequently results in the reduction of nerve terminal excitability and downstream vdcc activation through a signaling cascade involving pka. |
2009-04-21 |
2023-08-12 |
human |
| Jun Soo Kwon, Euitae Kim, Do-Hyung Kang, Jung Seok Choi, Kyung-Sang Yu, In-Jin Jang, Sang-Goo Shi. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 18. issue 12. 2009-04-20. PMID:18786813. |
taq1a polymorphism in the dopamine d2 receptor gene as a predictor of clinical response to aripiprazole. |
2009-04-20 |
2023-08-12 |
Not clear |